Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
Palatin Technologies saw an 8.41% after-hours stock price increase following a Janus Henderson Group 13G filing revealing a 9.99% ownership stake in the company.
PHARMACEUTICAL PREPARATIONS
PTN
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
Open XNAS
Key company ratios and reported financial statements.
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q4 FY2026 Jun 30, 2026 | Q3 FY2026 Mar 31, 2026 | Q2 FY2026 Dec 31, 2025 | Q1 FY2026 Sep 30, 2025 | Q4 FY2025 Jun 30, 2025 | Q3 FY2025 Mar 31, 2025 | Q2 FY2025 Dec 31, 2024 | Q1 FY2025 Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300.77K | $3.92M | $116.04K | $8.85M | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $300.77K | $3.92M | $116.04K | $8.85M | $0 | $0 | $0 | $0 |
| Selling, general and administrative | $2.71M | $1.98M | $3.12M | $1.66M | $2.63M | $1.47M | $1.68M | $2.02M |
| Research and development | $2.01M | $3.52M | $4.32M | $2.53M | $1.97M | $3.76M | $3.43M | $5.74M |
| Total operating expenses | $4.72M | $5.5M | $7.44M | $4.19M | $2.9M | $4.81M | $5.11M | $7.76M |
| Operating income | -$4.42M | -$1.58M | -$7.33M | $4.66M | -$2.9M | -$4.81M | -$5.11M | -$7.76M |
| Interest expense | -$2.96K | -$1.27K | -$498 | -$2K | -$3.49K | -$1.8K | -$3.8K | -$5.94K |
| Income before taxes | -$4.36M | -$1.43M | -$7.26M | $4.68M | -$2.23M | -$4.81M | -$2.44M | -$7.82M |
| Income taxes | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.36M | -$1.43M | -$7.26M | $4.68M | -$2.23M | -$4.81M | -$2.44M | -$7.82M |
| Net income attributable to common shareholders | -$4.36M | -$1.43M | -$7.26M | $4.68M | -$2.23M | -$4.81M | -$2.44M | -$7.82M |
| EBITDA | -$4.4M | -$1.56M | -$7.31M | $4.68M | -$2.85M | -$4.76M | -$5.04M | -$7.68M |
| Basic earnings per share | -$1.12 | -$0.37 | -$2.86 | $4.81 | -$2.73 | -$9.13 | -$5.92 | -$19.71 |
| Diluted earnings per share | -$1.16 | -$0.37 | -$2.86 | $4.26 | -$2.73 | -$9.13 | -$5.92 | -$19.71 |
Company coverage with links to the original publishers.
Palatin Technologies saw an 8.41% after-hours stock price increase following a Janus Henderson Group 13G filing revealing a 9.99% ownership stake in the company.
Palatin Technologies presented positive data from its Phase 3 MELODY-1 clinical trial of PL9643 for the treatment of dry eye disease, showing statistically significant symptom improvement and ocular surface health benefits.
The 13th edition of the Hotel & Hospitality Expo Saudi Arabia will be held from April 8-10, 2025 in Riyadh. The event is expected to attract over 8,000 industry professionals and showcase the latest innovations and trends in the hospitality sector, as Saudi Arabia aims to achieve its Vision 2030 goals.
The 13th edition of the Hotel & Hospitality Expo Saudi Arabia is set to return in 2025, showcasing the Kingdom's booming tourism sector and contributing to its Vision 2030 objectives. The event will feature exhibitors from 26 countries and is expected to attract 8,000 industry professionals.
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Historical share-structure events and their execution dates.
| Execution date | Split ratio | Event type |
|---|---|---|
| Aug 31, 2022 | 1-for-25 | reverse split |
| Sep 27, 2010 | 1-for-10 | reverse split |